This is the standing evidence sheet for Arcutis Biotherapeutics (ARQT): the yardsticks BullScope computes from official SEC filings and market prices. It refreshes whenever a new edition of our research is published, and it is impersonal by design, every reader sees the same page. Nothing here is investment advice; it is the evidence, organized.
The price tag: what buyers pay per dollar of profit
Arcutis Biotherapeutics is priced at 8.5× its annual sales (typical for this company over its past decade: 9.3×).
The tape: what the stock itself has done
- Last price: $25.16 (end-of-day market data as of the edition date · methodology) · 19% below its 52-week high
- Past 6 months: +6.5% · past 12 months: +27.3%
- Day-to-day temperament: jumpy (annualized volatility 57%)
The filed record: straight from the annual reports
| Fiscal year | Revenue | Growth | Operating margin | EPS |
|---|---|---|---|---|
| FY2024 | $0.2B | , | -65.3% | $-1.16 |
| FY2025 | $0.4B | +91.3% | -3.3% | $-0.13 |
The road ahead: filed results vs published expectations
| FY2023A | FY2024A | FY2025A | FY2026E | FY2027E | |
|---|---|---|---|---|---|
| Net sales ($B) | 0.03 | 0.20 | 0.40 | 0.50 to 0.57 | 0.57 to 0.72 |
| Net sales growth (%) | NM | +567 | +100 | 25 to 43 | 14 to 32 |
| Operating margin (%) | -667 | -50 | -3.3 | 2.0 to 6.0 | 4.0 to 10.0 |
| Diluted EPS ($) | -3.78 | -1.16 | -0.13 | 0.05 to 0.45 | -0.10 to 0.70 |
Columns marked A are actual filed results; E columns are the published consensus ranges the current price is being weighed against.
The four gauges: from the latest edition
Read the full report on Arcutis Biotherapeutics in the BullScope Terminal → It opens with this company loaded.
Edition date: 2026-08-21. This page updates when a new edition is published. Sources: SEC EDGAR filings, Nasdaq prices; computed by BullScope’s published methodology.
